The market is thawing, but not in the anything-goes way biotech learned to expect in 2021. Kailera Therapeutics and Alamar Biosciences suggest public investors are back—just on far stricter terms.
On April 13, two very different companies stepped into the U.S. IPO market. Kailera Therapeutics, an obesity-drug developer, launched its offering targeting a valuation of as much as $1.9 billion. Alamar Biosciences, a proteomics tools company, began marketing an IPO that could value it at up to $1.1 billion. At first glance, that can look like a routine burst of capital-markets activity. It is not. Taken together, the two deals say something larger about biotech in 2026: the IPO drought is easing, but the market that is reopening is narrower, more disciplined, and far less forgiving than the one that existed during the pandemic-era boom.
That distinction matters. In the first quarter of 2026, six biotech companies that priced IPOs raised a combined $1.7 billion, the strongest quarter for biotech IPO proceeds since 2021, with a median raise of $287.5 million. That is a real improvement. But it is also worth remembering the hole the sector is climbing out of: U.S. biotech IPO proceeds in 2025 totaled just $1.6 billion, versus $16 billion in 2021, and Dealogic counted only 10 biotech IPOs last year. In other words, the recovery is visible in dollars before it is visible in deal breadth. Money isreturning, but selectively.
This is not 2021 again
The easiest mistake right now is to confuse reopening with revival. The public market is not behaving as though biotech has returned to the speculative excess of the pandemic years, when companies with thin data packages and expansive platform narratives could often list on promise alone. The pattern in 2026 has been almost the opposite. BioPharma Dive’s first-quarter review found that all but one of this year’s biotech IPOs involved companies with drugs in mid- or late-stage clinical testing, and that no preclinical biotech has gone public since 2024. Public capital is available again, but it is behaving more like crossover capital than venture capital. It wants proof, not just possibility.
That shift may be healthier for the public market, but it is also more revealing than many founders or bankers would like to admit. It suggests that biotech’s IPO window is reopening on investors’ terms, not issuers’ terms. The market is effectively saying: bring us a company we can model, a catalyst we can date, a commercial category we already understand, or a revenue line we can measure. The romantic version of biotech finance—the idea that public markets exist to fund scientific uncertainty at scale—has not exactly returned. What is returning is a more conservative version of public biotech investing, one built around legibility.
Why the window is opening now
Part of this thaw is macro. The SPDR S&P Biotech ETF, a widely watched gauge of the sector, ended 2025 up 33%, helping restore confidence after a bruising stretch. PitchBook argued in its 2026 healthcare outlook that improving M&A, additional rate cuts, and the second-half rebound in biotech equities should help thaw the IPO market further in 2026. Reuters reported in January that lower rates had already reopened the secondary-offering market in the back half of 2025. More recently, the VIX fell below 20, a level many market participants read as a sign of improved stability. None of that guarantees smooth issuance, but it does explain why companies that waited through 2025 are finally testing the tape.
But macro alone does not explain why certain biotech stories are clearing the hurdle while others still cannot. For that, it helps to look closely at the companies moving first.
The new public-market biotech is either de-risked science or visible revenue
Kailera is practically a case study in what public investors currently want. It sits in obesity, the hottest large-market therapeutic category in biotech. Its lead asset, ribupatide, is already in global Phase 3 trials, and the company has moved additional obesity candidates forward as well, including a Phase 2 trial for KAI-7535 that began in April. The IPO structure tells the same story: Kailera is offering 33.3 million shares at $14 to $16 apiece, with Bain Capital and the Qatar Investment Authority indicating interest in buying up to $225 million worth. That is not just an obesity story. It is an obesity story wrapped in late-stage development, large-category familiarity, and anchor-investor validation. Public investors do not have to imagine a future market from scratch; they only have to decide whether Kailera deserves a place inside one they already believe exists.
Alamar, by contrast, represents a different but equally instructive path to the public market. It is not asking investors to underwrite a binary therapeutic readout. It is offering exposure to proteomics and diagnostics through a business that already has measurable commercial traction. In its amended S-1, Alamar reported 2025 revenue of $74.2 million, up 195% from $25.1 million in 2024. Gross margin expanded to 56% from 34%, net loss narrowed to $29.8 million from $47.1 million, and its installed base grew to more than 100 instruments by the end of 2025. This is still a growth company, not a mature cash machine. But it is also a reminder that one reason biotech IPOs may be working again is that some issuers are no longer selling only science; they are selling revenue visibility, recurring consumables demand, and a clearer operating model.
That is the deeper signal from Kailera and Alamar together. The reopening window is not rewarding one narrow scientific theme. It is rewarding one narrow financial principle: investors want biotech stories that can be explained in public-market language. Sometimes that means late-stage obesity. Sometimes it means commercial proteomics. In both cases, the common thread is not novelty. It is underwritability.
The IPO is back. The aftermarket is still skeptical.
That becomes obvious the moment you look beyond the offering itself. Eikon Therapeutics raised $381.2 million in February at $18 a share. Generate Biomedicines raised $400 million later that month at $16. Agomab Therapeutics raised $200 million at $16 as well. Yet as of April 15, Eikon was trading around $10.61, Generate around $12.89, and Agomab around $10.47—each below its IPO price. That does not mean those IPOs failed. It means the market is open but demanding. Investors are willing to fund biotech companies again, but they are also willing to reprice them quickly once the roadshow ends and the public market takes over.
This is why the current moment is better described as a selective reopening than a comeback. Biotech has regained access to the public market, but not on founder-friendly terms. Bankers can get deals done. Companies can raise meaningful capital. Yet valuations remain restrained, aftermarket performance is uneven, and the burden of proof has shifted decisively back onto issuers. That is probably what a normal market should look like. But for a sector that grew used to being financed on potential, the normalization feels almost austere.
What this means for biotech next
There is a reason this matters beyond capital-markets gossip. IPOs are not just exit events. In biotech, they are part of the sector’s financing machinery. They recycle venture capital into the next generation of companies, establish public valuations that influence private rounds, and help late-stage developers fund expensive registrational programs. When that machinery stalls, pressure builds across the entire innovation chain. PitchBook noted that early-stage biotech funding remains depressed even as M&A and IPO conditions improve. If only the most legible, late-stage, category-approved companies can make it out, then earlier and stranger forms of innovation may remain capital constrained for longer.
That is the more provocative question beneath the current optimism. Is biotech getting a healthier IPO market—or just a narrower one? If the answer is narrowness, then 2026 may still be a good year for offerings without becoming a great year for scientific risk-taking. The market may be reopening for biotech businesses, not necessarily for biotech experimentation. The real test will come later in the year, when more awkward categories try their luck: platform biotechs, earlier-stage assets, and segments like cell and gene therapy that have struggled to find public-market sponsorship. Until then, the message from Kailera and Alamar is clear enough. The window is opening. But it is not opening for everyone.
